Rep. Kevin Hern Sells Off Medtronic PLC (NYSE:MDT) Shares

Posted by Renee Jackson on Sep 3rd, 2026

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on August 24th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 8/18/2026.
Sold $1,001 – $15,000 in shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 8/18/2026.

Medtronic Stock Up 0.1%

Shares of NYSE:MDT opened at $92.10 on Thursday. The firm has a market cap of $117.89 billion, a PE ratio of 22.69, a price-to-earnings-growth ratio of 2.15 and a beta of 0.56. The company has a fifty day simple moving average of $86.27 and a 200 day simple moving average of $85.35. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period last year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.96 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.

Hedge Funds Weigh In On Medtronic

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC raised its stake in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its position in Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares in the last quarter. Jump Financial LLC acquired a new stake in Medtronic in the 2nd quarter valued at about $299,000. Main Street Financial Solutions LLC lifted its holdings in Medtronic by 28.9% in the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after acquiring an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its position in shares of Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after purchasing an additional 3,376 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Broad earnings beat and stronger outlook: Medtronic reported adjusted EPS of $1.45, above the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates of $9.55 billion. Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Medtronic fiscal 2027 results
Positive Sentiment: Growth was broad-based: Cardiovascular revenue rose 19.5%, neuroscience increased 10.3%, medical surgical grew 10.0% and diabetes advanced 16.9%. Analysts characterized the results as evidence of a potential growth acceleration across both established franchises and newer platforms. Medtronic beat-and-raise analysis
Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining distribution rights for its Sentire surgical system in select markets outside the United States. It also agreed to invest up to $80 million in Pi-Cardia to support complex TAVR procedures. These moves could broaden Medtronic’s long-term growth opportunities in minimally invasive surgery and structural heart care. Cornerstone Robotics partnership
Positive Sentiment: Analyst support increased: RBC reaffirmed an Outperform rating and set a $118 price target. BTIG raised its target to $100 and maintained a Buy rating, while Baird lifted its target to $100. These revisions indicate improving confidence in Medtronic’s earnings trajectory. Analyst price-target revisions
Neutral Sentiment: Some caution remains: Stifel raised its price target to $95 but kept a Hold rating, and Baird retained a Neutral rating despite its higher target. The second-quarter EPS outlook of $1.32-$1.34 is below the $1.35 consensus, suggesting investors may continue to watch execution and the sustainability of the recent growth acceleration.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Bank of America lifted their target price on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday. Rothschild & Co Redburn cut their target price on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. JPMorgan Chase & Co. dropped their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Sanford C. Bernstein dropped their price target on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Finally, Mizuho set a $115.00 price target on Medtronic in a report on Wednesday. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.96.

View Our Latest Stock Report on Medtronic

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by insiders.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).